5/30/2008 10:06:30 AM
HUNTINGDON VALLEY, Pa. & CHICAGO--(BUSINESS WIRE)--The Circulating Tumor Cell technology developed by Immunicon Corporation (OTCBB:IMMC) will be the subject of 12 abstracts presented in a variety of applications at the 44th annual American Society of Clinical Oncology (ASCO) conference, the premier educational and scientific event in the oncology community. The conference takes place on May 30-June 3 at the McCormick Place Convention Complex in Chicago, Illinois. The presentations will detail results of research using the CellSearch™ System and Circulating Tumor Cells (CTCs) to predict disease progression and outcome in patients with breast and prostate cancers as well as patients with lung and bladder cancers. The abstracts include work by Immunicon researchers as well as studies conducted by pharmaceutical companies and research institutes.
comments powered by